$RAFA News Out SANDY, UT--(Marketwired - Apr 8,

$RAFA News Out SANDY, UT--(Marketwired - Apr 8, 2013) - Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA), a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today announces that ZAO "Rafarma" has registered (MHH) CEFTRIAXONE, a third-generation cephalosporin antibiotic, as a medication under international unpatented label.

CEFTRIAXONE is most often used in combination for the treatment of pneumonia, bacterial meningitis, gonorrhea, and in pediatrics for the prevention of sepsis. Market capacity of CEFTRIAXONE in the Russian Federation in 2012 was USD $85.7 million dollars, an increase of 20% compared to its capacity in 2011.

Dave Anderson, CEO of Rafarma Pharmaceuticals, said, "Registering this product is complementary to our goal of producing high-quality pharmaceutical products. Rafarma is positioned to meet rising market demand for CEFTRIAXONE utilizing our state-of-the-art research facility and staff as we continue efforts to expand our product portfolio."

"I'd also like to clarify that Rafarma's earlier announcement reporting its status as 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation in no way limits our ability to produce and manufacture products for qualified buyers globally," added Mr. Anderson. "We will offer CEFTRIAXONE, as well as all other products we produce, to the international market."

About Rafarma Pharmaceuticals, Inc.

Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.

To view additional information on Rafarma Pharmaceuticals, visit: www.rafarma.com

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/Rafarmainfo and www.twitter.com/Rafarmainfo